CA2680249A1 - Mesylate d'imatinib - Google Patents

Mesylate d'imatinib Download PDF

Info

Publication number
CA2680249A1
CA2680249A1 CA002680249A CA2680249A CA2680249A1 CA 2680249 A1 CA2680249 A1 CA 2680249A1 CA 002680249 A CA002680249 A CA 002680249A CA 2680249 A CA2680249 A CA 2680249A CA 2680249 A1 CA2680249 A1 CA 2680249A1
Authority
CA
Canada
Prior art keywords
solid dispersion
imatinib
imatinib mesylate
methyl
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002680249A
Other languages
English (en)
Inventor
Surya Narayana Devarakonda
Minakshi Asnani
Munaswamy Sekhar Nariyam
Arjun Kumar Tummala
Vamsi Krishna Mudapaka
Srinivas Benda
Subba Reddy Peddireddy
Balaji Raghupati
Raghavendracharyulu Venkata Palle
Subrahmanyam Raghupati Rama Vinjamuri
Vijay Bhailalbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr. Reddy's Laboratories, Inc.
Dr. Reddy's Laboratories Ltd.
Surya Narayana Devarakonda
Minakshi Asnani
Munaswamy Sekhar Nariyam
Arjun Kumar Tummala
Vamsi Krishna Mudapaka
Srinivas Benda
Subba Reddy Peddireddy
Balaji Raghupati
Raghavendracharyulu Venkata Palle
Subrahmanyam Raghupati Rama Vinjamuri
Vijay Bhailalbhai Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories Ltd., Surya Narayana Devarakonda, Minakshi Asnani, Munaswamy Sekhar Nariyam, Arjun Kumar Tummala, Vamsi Krishna Mudapaka, Srinivas Benda, Subba Reddy Peddireddy, Balaji Raghupati, Raghavendracharyulu Venkata Palle, Subrahmanyam Raghupati Rama Vinjamuri, Vijay Bhailalbhai Patel filed Critical Dr. Reddy's Laboratories, Inc.
Publication of CA2680249A1 publication Critical patent/CA2680249A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
CA002680249A 2007-03-12 2008-03-12 Mesylate d'imatinib Abandoned CA2680249A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN497CH2007 2007-03-12
IN497/CHE/2007 2007-03-12
IN2149CH2007 2007-09-24
IN2149/CHE/2007 2007-09-24
US97917207P 2007-10-11 2007-10-11
US60/979,172 2007-10-11
PCT/US2008/056588 WO2008112722A2 (fr) 2007-03-12 2008-03-12 Mésylate d'imatinib

Publications (1)

Publication Number Publication Date
CA2680249A1 true CA2680249A1 (fr) 2008-09-18

Family

ID=39705055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002680249A Abandoned CA2680249A1 (fr) 2007-03-12 2008-03-12 Mesylate d'imatinib

Country Status (10)

Country Link
US (1) US20100087444A1 (fr)
EP (1) EP2120877A2 (fr)
JP (1) JP2010521477A (fr)
KR (1) KR20090128396A (fr)
CN (1) CN101677955A (fr)
BR (1) BRPI0808840A2 (fr)
CA (1) CA2680249A1 (fr)
IL (1) IL200848A0 (fr)
MX (1) MX2009009659A (fr)
WO (1) WO2008112722A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2305263B1 (fr) * 2007-06-07 2012-09-19 Novartis AG Formes amorphes stabilisées du mésylate de l'imatinib
WO2009080366A1 (fr) * 2007-12-22 2009-07-02 Synthon B.V. Procédé de fabrication d'imatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
EA024088B1 (ru) * 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012004801A1 (fr) * 2010-07-07 2012-01-12 Hetero Research Foundation Procédé de préparation de mésylate d'imatinib
CN101921260B (zh) * 2010-09-16 2013-01-16 山东金城医药化工股份有限公司 一种伊马替尼的制备方法
CN101985442B (zh) * 2010-09-19 2013-04-03 南京卡文迪许生物工程技术有限公司 一种便捷的制备高纯度的伊马替尼及其甲磺酸盐的方法
KR101139431B1 (ko) * 2011-05-30 2012-04-27 (주)비씨월드제약 이매티닙 염기의 신규한 제조방법
EP2782560A1 (fr) 2011-11-24 2014-10-01 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Formes posologiques solides à base d'imatinib reconstituées juste avant l'utilisation
IN2012CH01309A (fr) * 2012-04-02 2015-06-19 Hetero Research Foundation
EP2749269A1 (fr) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Procédé pour la préparation d'adsorbés de imatinib
CN104888228A (zh) * 2015-05-29 2015-09-09 连云港杰瑞药业有限公司 一种甲苯磺酸索拉非尼固体分散体及其制备方法
RU2020108342A (ru) 2017-07-26 2021-08-26 Эф Тэ Эф Фарма Привейт Лимитед Жидкие дозируемые лекарственные формы иматиниба
JP2022534610A (ja) * 2019-05-31 2022-08-02 江蘇恒瑞医薬股▲ふん▼有限公司 固体分散体およびその調製方法
US20220265653A1 (en) 2019-07-15 2022-08-25 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib
CN110693839B (zh) * 2019-11-19 2022-03-08 乐普药业股份有限公司 一种甲磺酸仑伐替尼固体分散体及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
WO2006040779A2 (fr) * 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
BRPI0613540A2 (pt) * 2005-06-03 2011-01-18 Elan Pharma Int Ltd formulações de imatinib mesilato nanoparticuladas
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
WO2008027600A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib

Also Published As

Publication number Publication date
MX2009009659A (es) 2009-09-22
BRPI0808840A2 (pt) 2014-09-02
WO2008112722A2 (fr) 2008-09-18
US20100087444A1 (en) 2010-04-08
CN101677955A (zh) 2010-03-24
IL200848A0 (en) 2010-05-17
JP2010521477A (ja) 2010-06-24
WO2008112722A3 (fr) 2008-11-06
EP2120877A2 (fr) 2009-11-25
KR20090128396A (ko) 2009-12-15

Similar Documents

Publication Publication Date Title
US20100087444A1 (en) Imatinib mesylate
US20140121245A1 (en) Anhydrous lenalidomide form-i
AU2009314512B2 (en) Lenalidomide solvates and processes
CA2480352A1 (fr) Polymorphes de lansoprazole et procedes de preparation de ces derniers
WO2016178150A1 (fr) Nouveaux polymorphes d'axitinib
WO2012015999A2 (fr) Procédé de préparation de mésylate d'imatinib
WO2019209633A1 (fr) Formes à l'état solide de lorlatinib et préparation associée
US20110015247A1 (en) Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US8252926B2 (en) Process for the preparation of imatinib base
WO2006131338A2 (fr) Solvate cristallin de sodium d'omeprazole
CA2518999A1 (fr) Formes solides cristallines et amorphes de pantoprazole et procedes de preparation de ces formes
AU2007309558B2 (en) Crystal modifications -3- (1H-indol-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-dione
EA011713B1 (ru) Получение гидрохлоридов производного тетразола
EP1598347A1 (fr) Polymorphes du sel de sodium de pantoprazole et procédé de préparation
WO2006098834A9 (fr) Formes cristallines de mesylate de ziprasidone
EP1768969B1 (fr) Mycophenolate de sodium cristallin
US7977330B2 (en) Salts and crystal modifications thereof
WO2019008604A1 (fr) Nouvelles formes d'agoniste du récepteur mu-opioïde
WO2007038677A2 (fr) Procedes de preparation de ladostigil tartrate cristallise forme a1
EP3873214A1 (fr) Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140312